Press releases & news


The PARP inhibitor Olaparib significantly improves the five-year survival of patients with newly diagnosed advanced ovarian cancer.


Results from the first double-blinded randomized phase III-trial (SOLO-1) between the PARP inhibitor Olaparib and standard chemotherapy showed a clear benefit of PARP inhibition (presentation ID 811MO by Dr. S. Banerjee et al.). The median progression free survival was thus 56 months for PARP treated patients as compared to 14 months for the placebo group. This and other studies open for a new era in the management of recurrent ovarian cancer (download abstract (pdf)).

This highly encouraging result opens for a number of questions: How do the other PARP inhibitors compare to Olaparib; Is there a need to individualizing PARP treatment using a Functional Precision Medicine tool like IndiTreat.


Contact information

2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark| Phone: +45 2211 5399| E-mail:

Privacy Policy | Imprint